New Indazole Derivatives as Potential Scaffolds for the Development of Anticancer, Antiviral, and Anti-tuberculosis Chemotherapeutic Compounds

Introduction: Chemotherapy remains essential despite advances in immunotherapy, radiotherapy, and biological therapy. However, the wide range of chemical drugs is limited by a narrow therapeutic index, low selectivity, and the development of resistance. In this regard, new high-efficiency drugs are in extremely high demand. The indazole moiety, a scaffold found in many biologically active compounds, was selected for use in new drug design. Methods: Six new indazole derivatives were synthesized via Suzuki-Miyaura coupling starting from bromoindazole. Their antiviral (against influenza A and SARS-CoV-2), antibacterial (against M. tuberculosis), and antiproliferative activities (against neuroblastoma, glioma, leukemia cell lines) were evaluated in vitro. Acute toxicity was assessed in mice of both sexes via single intragastric administration, with toxicometric parameters and pathomorphological changes studied. Results: 6-(1H-pyrazol-4-yl)-1H-indazole (8) suppressed the reproduction of the influenza virus at non-toxic doses to the MDCK cells and showed cytotoxicity against cancer cell lines, with an IC50between 4 and 14 µM. However, it exhibited significant acute toxicity in mice (LD5040 mg/kg), causing systemic organ damage. Discussion: Derivative 8 demonstrated promising antiviral and antiproliferative activities but exhibited considerable acute toxicity in vivo. The antiviral efficacy, although lower than oseltamivir, is meaningful and justifies further optimization and investigation. Its antibacterial activity against M. tuberculosis adds to its potential as a multifunctional agent. Conclusion: While derivative 8 has shown potential as an antiviral and anticancer agent, its high toxicity highlights the need for further studies to define a safe and effective therapeutic window. Overall, the indazole scaffold remains a valuable platform for the development of new therapeutic compounds. The Author(s). © 2025 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode.

Авторы
Khandazhinskaya Anastasia L. 1 , Kondrashova Evgenia 1 , Sokhraneva Vera A. 1 , Novikova Ol'ga P. 2 , Velikorodnaya Yulia 2 , Gorshenin Andrey 2 , Andreevskaya Sofya N. 3 , Smirnova Tat'yana G. 3 , Moroz Maxim 4 , Kirillov Ilya M. 5 , Fedyakina Irina T. 5 , Chizhov Alexander O. 6 , Kochetkov Sergey N. 1 , Matyugina Elena S. 1
Издательство
Bentham Science Publishers B.V.
Язык
Английский
Статус
Опубликовано
Год
2025
Организации
  • 1 Laboratory of Molecular Basis of Action of Physiologically Active Compounds, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russian Federation
  • 2 Laboratory of Immunology, Research Institute of Hygiene, Toxicology and Occupational Pathology, Volgograd, Volgograd Oblast, Russian Federation
  • 3 Department of Microbiology, Central Institute of Tuberculosis, Russian Academy of Medical Sciences, Moscow, Moscow Oblast, Russian Federation
  • 4 School of Medicine, RUDN University, Moscow, Moscow Oblast, Russian Federation
  • 5 Laboratory of Virus Ecology, N. F. Gamaleya Institute of Epidemiology and Microbiology, Ministry of Health of the Russian Federation, Moscow, Russian Federation
  • 6 Laboratory of Mass Spectrometry, N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation
Ключевые слова
anticancer activity; antiviral compounds; drug design; Indazole derivatives; inhibition; Mycobacterium tuberculosis
Цитировать
Поделиться

Другие записи